Prevention and Treatment of Oral Mucositis in Cancer Patients Using Photobiomodulation (Low-Level Laser Therapy and Light-Emitting Diodes)

  • Cesar Augusto MiglioratiEmail author


Oral mucositis (OM) is one of the most impacting oral complications negatively affecting the quality of life of cancer patients being treated with high-dose chemotherapy and radiation of the head and neck. It is an acute adverse effect that can be devastating and could affect cancer prognosis. Prevention and management strategies have not been successful. Photobiomodulation is a form of light therapy delivered to human tissues by lasers, light-emitting diodes, and even broadband light. It interferes in the way human cells repair tissues in a nonthermal and nonionizing fashion. There is mounting evidence that photobiomodulation (PBM or low-level laser therapy) can be effective in preventing OM and/or reducing the severity of this important complication. This chapter describes current modeling of the pathobiology and clinical characteristics of OM, the burden on the cancer patient, and the use of PBM as a preventative and/or therapeutic management of this oral complication.


Oral mucositis Photobiomodulation Laser therapy Low-level laser therapy Oral complications of cancer therapy 


  1. 1.
    Arany PR. Photobiomodulation therapy: communicating with stem cells for regeneration? Photomed Laser Surg. 2016;34(11):497–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Arany PR. Craniofacial wound healing with photobiomodulation therapy: new insights and current challenges. J Dent Res. 2016;95(9):977–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009;45(12):1015–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl):2026–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Eduardo FP, Bezinelli L, Luiz AC, Correa L, Vogel C, Eduardo CP. Severity of oral mucositis in patients undergoing hematopoietic cell transplantation and an oral laser phototherapy protocol: a survey of 30 patients. Photomed Laser Surg. 2009;27(1):137–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5(9 Suppl 4):3–11.PubMedGoogle Scholar
  7. 7.
    Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Sonis ST. Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid. 2010;4:199–205.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin N Am. 2008;52(1):61–77, viiiPubMedCrossRefGoogle Scholar
  10. 10.
    Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.PubMedCrossRefGoogle Scholar
  11. 11.
    Sonis ST. Pathobiology of mucositis. Semin Oncol Nurs. 2004;20(1):11–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Fox BS, Sonis S. TNF and oral mucositis: response to effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 2009; 92:472–6. Radiother Oncol. 2010;94(1):123; author reply -4PubMedCrossRefGoogle Scholar
  13. 13.
    Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43(4):395–401.PubMedCrossRefGoogle Scholar
  14. 14.
    Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33(5):448–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16(7):597–600.PubMedCrossRefGoogle Scholar
  16. 16.
    McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14(6):541–7.PubMedCrossRefGoogle Scholar
  17. 17.
    McGuire DB, Johnson J, Migliorati C. Promulgation of guidelines for mucositis management: educating health care professionals and patients. Support Care Cancer. 2006;14(6):548–57.PubMedCrossRefGoogle Scholar
  18. 18.
    Migliorati C, Hewson I, Lalla RV, Antunes HS, Estilo CL, Hodgson B, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):333–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–61.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. 2007;15(10):1145–54.PubMedCrossRefGoogle Scholar
  21. 21.
    Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337–61.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Passarella S, Karu T. Absorption of monochromatic and narrow band radiation in the visible and near IR by both mitochondrial and non-mitochondrial photoacceptors results in photobiomodulation. J Photochem Photobiol B. 2014;140:344–58.PubMedCrossRefGoogle Scholar
  23. 23.
    Hamblin MR. Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochem Photobiol. 2018;94(2):199–212.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Lane N. Cell biology: power games. Nature. 2006;443(7114):901–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Bjordal JM, Bensadoun RJ, Tuner J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19(8):1069–77.PubMedCrossRefGoogle Scholar
  26. 26.
    Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Elad S, Hamblin MR, et al. Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Support Care Cancer. 2016;24(6):2793–805.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Bjordal JM. Low level laser therapy (LLLT) and World Association for Laser Therapy (WALT) dosage recommendations. Photomed Laser Surg. 2012;30(2):61–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Antunes HS, de Azevedo AM, da Silva Bouzas LF, Adao CA, Pinheiro CT, Mayhe R, et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood. 2007;109(5):2250–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Antunes HS, Herchenhorn D, Small IA, Araujo CM, Viegas CM, Cabral E, et al. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol. 2013;109(2):297–302.PubMedCrossRefGoogle Scholar
  30. 30.
    Silva GB, Mendonca EF, Bariani C, Antunes HS, Silva MA. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg. 2011;29(1):27–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Freire Mdo R, Freitas R, Colombo F, Valenca A, Marques AM, Sarmento VA. LED and laser photobiomodulation in the prevention and treatment of oral mucositis: experimental study in hamsters. Clin Oral Investig. 2014;18(3):1005–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Weissheimer C, Curra M, Gregianin LJ, Daudt LE, Wagner VP, Martins MAT, et al. New photobiomodulation protocol prevents oral mucositis in hematopoietic stem cell transplantation recipients-a retrospective study. Lasers Med Sci. 2017;32(9):2013–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G, et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg. 2002;20(6):319–24.PubMedCrossRefGoogle Scholar
  34. 34.
    Hodgson BD, Margolis DM, Salzman DE, Eastwood D, Tarima S, Williams LD, et al. Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients. Support Care Cancer. 2012;20(7):1405–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Sonis ST, Elad S, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer. 2016;24(6):2781–92.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Tuner J, Jenkins PA. Parameter reproducibility in photobiomodulation. Photomed Laser Surg. 2016;34(3):91–2.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Sonis ST, Hashemi S, Epstein JB, Nair RG, Raber-Durlacher JE. Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 2016;54:7–14.PubMedCrossRefGoogle Scholar
  38. 38.
    MT EL, JG EL, de Andrade MF, Bergmann A. Low-level laser therapy in secondary lymphedema after breast cancer: systematic review. Lasers Med Sci. 2014;29(3):1289–95.CrossRefGoogle Scholar
  39. 39.
    Antunes HS, Herchenhorn D, Small IA, Araujo CMM, Viegas CMP, de Assis Ramos G, et al. Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncol. 2017;71:11–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Bezinelli LM, de Paula Eduardo F, da Graca Lopes RM, Biazevic MG, de Paula Eduardo C, Correa L, et al. Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation. Hematol Oncol. 2014;32(1):31–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Bezinelli LM, Eduardo FP, Neves VD, Correa L, Lopes RM, Michel-Crosato E, et al. Quality of life related to oral mucositis of patients undergoing haematopoietic stem cell transplantation and receiving specialised oral care with low-level laser therapy: a prospective observational study. Eur J Cancer Care. 2016;25(4):668–74.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Oral and Maxillofacial Diagnostic SciencesUniversity of Florida College of DentistryGainesvilleUSA

Personalised recommendations